Skip to main content
. 2020 Oct 2;21(19):7295. doi: 10.3390/ijms21197295
ACT adoptive cell-transfer
APC antigen presenting cell
APM antigen processing machinery
ATF1 activating transcriptor factor 1
ATP adenosine triphosphate
BiTES bi-specific T-cell engager antibodies
BLS bare lymphocyte disease
CAR chimeric antigen receptor
CIITA class II trans-activator
CIITA class I trans activator
CLIP class II-associated I chain peptide
CNX calnexin
CREB1 cAMP-responsive element binding protein 1
CRT calreticulin
CTL cytotoxic T lymphocyte
CTLA-4 cytotoxic T-lymphocyte antigen 4
DC dendritic cell
DFS disease free survival
DNMTi DNA methyltransferase inhibitor
EGFR epithelial growth factor receptor
ER endoplasmic reticulum
HDAC histone deacetylase
HLA human leukocyte antigen
ICI immune checkpoint inhibitor
IFN interferon
IRF IFN Regulatory Factor
ISRE IFN-sensitive response element
KIR killer cell immunoglobulin-like receptor
JAK janus kinase
LAG-3 lymphocyte activation gene 3
LMP low molecular weight protein
LOH loss of heterozygosity
mAb monoclonal antibody
MAPK mitogen-activated protein kinase
MEK MAPK/ERK kinase
MHC major histocompatibility complex
MIIC MHC class II compartment
NF-kB nuclear factor kB
NFY nuclear transcriptor factor Y
NK natural killer
NLRC5 NOD-like receptor 5
OS overall survival
PD-1 programmed cell death 1
PD-L1 programmed cell death ligand 1
PFS progression free survival
RFX regulatory factor X
RFXANK RFX-associated ankyrin-containing protein
RFXAP RFX associated protein
TAP transporters associated with antigen processing
TCR T-cell receptor
TKI tyrosine kinase inhibitor
TNF-α tumor necrosis factor alpha
TA tumor antigen
TAA tumor associated antigen
TAM Type II tumour-associated macrophages
TIL tumor-infiltrating lymphocyte
TME tumor microenvironment
Treg regulatory T cell
TSA tumor specific antigen
tsMHC-II tumor specific MHC class II
β2-m β2-microglobulin